Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device

Open Label Split Face Pilot Study to Assess the Safety and Efficacy of Cold Atmospheric Plasma (Non-thermal Plasma) for the Treatment of Rosacea

10-13 patients will be enrolled to receive split face treatment: the control side will be treated with metronidazole cream, the intervention side will be treated with a cold atmospheric plasma device

Inclusion Criteria:

• Papulopustular rosacea of the cheeks
• Ability to complete six weeks of twice-weekly treatments

Exclusion Criteria:

• substantial asymmetry of disease distribution
• previous failure of topical ivermectin treatment
• presence of any other facial dermatoses
• presence of any photosensitizing disorders
• systemic tetracycline, systemic or topical ivermectin treatment within 6 weeks of start date
• current or within prior 3 months treatment with systemic immune-suppressive medication